AWA’s client CellaVision has signed an agreement to acquire the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics.
CellaVision is an innovative, global medical technology company that develops and sells leading systems for routine analysis of blood and other body fluids in health care services.
AWA has worked with CellaVision for over 20 years, and we are proud to work with such an innovative client that is simplifying and automating laboratory work.
This acquisition gives CellaVision access and control of an interesting future technology and has a cash purchase price of SEK 28.7 million (USD 3.3 million).
The technology has been developed at the California Institute of Technology and is a method for creating high-resolution images with low-magnification optics. This enables images of large areas to be acquired at high resolution faster than conventional digital microscopy.
CellaVision believes that the Fourier Ptychography Microscopy technology has the potential to be used to develop future automated microscopes with applications in both hematology and adjacent areas.
The acquired patent rights provide protection in CellaVision’s key geographies for more than 12 years and AWA assisted by performing the necessary due diligence of these patents.
Julia Mannesson and Kristoffer Svensson led the team from AWA throughout the due diligence work.